Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Other
Enrollment
35actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-18 | actual | When the study began enrolling |
| Primary completion | 2026-06-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-15 | actual | The whole study's end, after follow-up |
| First posted | 2025-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Renal Impairment
Intervention
- Drug: Opemalirsen (AZD2373)
Primary outcomes
what the primary-completion date above is the date OFAUCinf
measured Pre-dose to 3 weeks post dose
AUClast
measured Pre-dose to 3 weeks post-dose
Cmax
measured Pre-dose to 3 weeks post-dose
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed